Disseminated intravascular coagulation in sepsis

Area of Science:

• Critical Care Medicine
• Hematology
• Sepsis Pathophysiology

Background:

• Disseminated intravascular coagulation (DIC) is a common and severe complication of sepsis.
• Sepsis-induced DIC involves dysregulated coagulation, impaired fibrinolysis, and consumption of anticoagulant proteins.
• Microvascular thrombosis and fibrin deposition in sepsis contribute to multi-organ dysfunction.

Purpose of the Study:

• To review the physiology and pathophysiology of coagulation and fibrinolysis in sepsis.
• To discuss therapeutic strategies for sepsis-associated DIC.
• To analyze recent randomized trials on anticoagulants in sepsis.

Main Methods:

• Review of physiological and pathophysiological mechanisms of coagulation and fibrinolysis.
• Discussion of therapeutic concepts for sepsis-induced DIC.
• Analysis of three randomized, double-blind, placebo-controlled trials: antithrombin, activated protein C (APC), and tissue factor pathway inhibitor.

Main Results:

• The pathophysiology of sepsis-induced DIC is characterized by a procoagulant state.
• Activated protein C (APC) demonstrated a significant reduction in mortality in a randomized trial of sepsis patients.
• Other agents like antithrombin and tissue factor pathway inhibitor were also investigated.

Conclusions:

• Understanding the complex interplay of coagulation and fibrinolysis is crucial for managing sepsis.
• Activated protein C (APC) represents a promising therapeutic intervention for sepsis, evidenced by improved survival rates.
• Further research into anticoagulation therapies for sepsis-induced DIC is warranted.